MCID: CRD194
MIFTS: 64

Cardiomyopathy, Familial Hypertrophic malady

Categories: Genetic diseases, Rare diseases, Cardiovascular diseases

Aliases & Classifications for Cardiomyopathy, Familial Hypertrophic

About this section

Aliases & Descriptions for Cardiomyopathy, Familial Hypertrophic:

Name: Cardiomyopathy, Familial Hypertrophic 52 70 35
Hypertrophic Cardiomyopathy 11 23 70 27 13 68
Familial Hypertrophic Cardiomyopathy 11 48 24 25 70
Cardiomyopathy, Familial Hypertrophic 1 11 70 27
Asymmetric Septal Hypertrophy 70 27 68
Cardiomyopathy, Familial Hypertrophic, 1 12 68
Cardiomyopathy, Hypertrophic, Familial 39 68
Heritable Hypertrophic Cardiomyopathy 48 25
Cmh1 11 70
Hcm 25 70
Hypertrophic Subaortic Stenosis, Idiopathic 70
Idiopathic Hypertrophic Subaortic Stenosis 25
Cardiomyopathy, Hypertrophic, 1, Digenic 52
 
Cardiomyopathy Hypertrophic Obstructive 50
Hypertrophic Obstructive Cardiomyopathy 11
Familial Asymmetric Septal Hypertrophy 25
Cardiomyopathy Familial Hypertrophic 48
Ventricular Hypertrophy, Hereditary 70
Hereditary Ventricular Hypertrophy 25
Cardiomyopathy, Hypertrophic, 1 52
Hypertrophic Cardiomyopathy 1 11
Cardiomyopathy, Hypertrophic 39
Familial Hcm 48
Ash 70
Fhc 70
Cmh 70

Characteristics:

HPO:

64
cardiomyopathy, familial hypertrophic:
Inheritance: autosomal dominant inheritance
Mortality/Aging: sudden death

Classifications:



Summaries for Cardiomyopathy, Familial Hypertrophic

About this section
OMIM:52 Hereditary ventricular hypertrophy (CMH, HCM, ASH, or IHSS) in early stages produces a presystolic gallop due to an... (192600) more...

MalaCards based summary: Cardiomyopathy, Familial Hypertrophic, also known as hypertrophic cardiomyopathy, is related to cardiomyopathy, familial hypertrophic, 9 and cardiomyopathy, hypertrophic, 20, and has symptoms including congestive heart failure, asymmetric septal hypertrophy and subaortic stenosis. An important gene associated with Cardiomyopathy, Familial Hypertrophic is MYH7 (Myosin Heavy Chain 7), and among its related pathways are Cardiomyocyte Differentiation through BMP Receptors and Translocation of GLUT4 to the plasma membrane. Affiliated tissues include heart, testes and endothelial, and related mouse phenotypes are cardiovascular system and muscle.

Disease Ontology:11 An intrinsic cardiomyopathy that has material basis in autosomal dominant inheritance and that is characterized by abnormal thickening (hypertrophy) of the heart without any obvious cause.

UniProtKB/Swiss-Prot:70 Cardiomyopathy, familial hypertrophic: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

Genetics Home Reference:25 Familial hypertrophic cardiomyopathy is a heart condition characterized by thickening (hypertrophy) of the heart (cardiac) muscle. Thickening usually occurs in the interventricular septum, which is the muscular wall that separates the lower left chamber of the heart (the left ventricle) from the lower right chamber (the right ventricle). In some people, thickening of the interventricular septum impedes the flow of oxygen-rich blood from the heart, which may lead to an abnormal heart sound during a heartbeat (heart murmur) and other signs and symptoms of the condition. Other affected individuals do not have physical obstruction of blood flow, but the pumping of blood is less efficient, which can also lead to symptoms of the condition. Cardiac hypertrophy often begins in adolescence or young adulthood, although it can develop at any time throughout life.

NIH Rare Diseases:48 Familial hypertrophic cardiomyopathy (HCM) is an inherited heart condition characterized by thickening of the heart muscle. The thickening most often occurs in the muscle wall that separates the left and right ventricles from each other (interventricular septum). This may restrict the flow of oxygen-rich blood from the heart, or it may lead to less efficient pumping of blood. Signs and symptoms can vary. While some people have no symptoms, others may have chest pain, shortness of breath, palpitations, lightheadedness, dizziness, and/or fainting. Even in the absence of symptoms, familial HCM can have serious consequences such as life-threatening arrhythmias, heart failure, and an increased risk of sudden death. Familial HCM may be caused by mutations in any of several genes and is typically inherited in an autosomal dominant manner. Treatment may depend on severity of symptoms and may include medications, surgical procedures, and/or an implantable cardioverter-defibrillator (ICD). Last updated: 12/28/2016

Wikipedia:71 Hypertrophic cardiomyopathy (HCM) is a disease in which a portion of the myocardium (heart muscle) is... more...

GeneReviews for NBK1768

Related Diseases for Cardiomyopathy, Familial Hypertrophic

About this section

Diseases in the Cardiomyopathy, Familial Hypertrophic family:

Cardiomyopathy, Hypertrophic, 20 Cardiomyopathy, Hypertrophic, 2
Cardiomyopathy, Familial Hypertrophic, 9 Cardiomyopathy, Hypertrophic, 13
Cardiomyopathy, Hypertrophic, 8 Cardiomyopathy, Hypertrophic, 16
Cardiomyopathy, Hypertrophic, 18 Cardiomyopathy, Hypertrophic 6
Cardiomyopathy, Hypertrophic, 15 Cardiomyopathy, Hypertrophic, 12
Cardiomyopathy, Hypertrophic, 4 Cardiomyopathy, Hypertrophic, 10
Cardiomyopathy, Hypertrophic, 14 Cardiomyopathy, Hypertrophic, 11
Cardiomyopathy, Hypertrophic, 3 Cardiomyopathy, Hypertrophic, 25
Cardiomyopathy, Hypertrophic, 19 Cardiomyopathy, Hypertrophic, 7
Cardiomyopathy, Hypertrophic, 17 Hypertrophic Cardiomyopathy 21
Hypertrophic Cardiomyopathy 26 Calr3-Related Familial Hypertrophic Cardiomyopathy
Jph2-Related Familial Hypertrophic Cardiomyopathy Actc1-Related Familial Hypertrophic Cardiomyopathy
Actn2-Related Familial Hypertrophic Cardiomyopathy Cav3-Related Hypertrophic Cardiomyopathy
Csrp3-Related Familial Hypertrophic Cardiomyopathy Mybpc3-Related Familial Hypertrophic Cardiomyopathy
Myh6-Related Familial Hypertrophic Cardiomyopathy Myh7-Related Familial Hypertrophic Cardiomyopathy
Myl2-Related Familial Hypertrophic Cardiomyopathy Myl3-Related Familial Hypertrophic Cardiomyopathy
Myoz2-Related Familial Hypertrophic Cardiomyopathy Nexn-Related Familial Hypertrophic Cardiomyopathy
Pln-Related Familial Hypertrophic Cardiomyopathy Tcap-Related Familial Hypertrophic Cardiomyopathy
Tnnc1-Related Familial Hypertrophic Cardiomyopathy Tnni3-Related Familial Hypertrophic Cardiomyopathy
Tnnt2-Related Familial Hypertrophic Cardiomyopathy Tpm1-Related Familial Hypertrophic Cardiomyopathy
Ttn-Related Familial Hypertrophic Cardiomyopathy Vcl-Related Familial Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy Due to Intensive Athletic Training

Diseases related to Cardiomyopathy, Familial Hypertrophic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 86)
idRelated DiseaseScoreTop Affiliating Genes
1cardiomyopathy, familial hypertrophic, 912.3
2cardiomyopathy, hypertrophic, 2011.7
3cardiomyopathy, hypertrophic, 211.7
4cardiomyopathy, hypertrophic, 1311.7
5cardiomyopathy, hypertrophic, 811.7
6cardiomyopathy, hypertrophic, 1611.7
7cardiomyopathy, hypertrophic, 1811.7
8cardiomyopathy, hypertrophic 611.7
9cardiomyopathy, hypertrophic, 1211.7
10cardiomyopathy, hypertrophic, 411.7
11cardiomyopathy, hypertrophic, 1011.7
12cardiomyopathy, hypertrophic, 1411.7
13cardiomyopathy, hypertrophic, 1111.7
14cardiomyopathy, hypertrophic, 311.7
15cardiomyopathy, hypertrophic, 711.7
16cardiomyopathy, hypertrophic, 1711.7
17cardiomyopathy, hypertrophic, 1511.7
18cardiomyopathy, hypertrophic, 1911.7
19cardiomyopathy, dilated, 1aa, with or without lvnc11.6
20cardiomyopathy, dilated, 1kk11.6
21cardiomyopathy, hypertrophic, 2511.6
22cardiomyopathy, dilated, 1c, with or without lvnc11.5
23cardiomyopathy, familial restrictive 511.5
24histiocytosis-lymphadenopathy plus syndrome11.2
25hypertrophic cardiomyopathy 2111.1
26calr3-related familial hypertrophic cardiomyopathy11.1
27vcl-related familial hypertrophic cardiomyopathy11.1
28jph2-related familial hypertrophic cardiomyopathy11.0
29nephronophthisis 1611.0
30hyperpigmentation with or without hypopigmentation11.0
31hypertrophic cardiomyopathy 2610.9
32tubular renal disease-cardiomyopathy syndrome10.9TNNI3, TNNT2
33myl2-related familial hypertrophic cardiomyopathy10.8MYH7, TPM1
34hypercholesterolemia, familial10.8
35fatal infantile hypertrophic cardiomyopathy due to mitochondrial complex i deficiency10.8
36scn5a-related dilated cardiomyopathy10.8MYH7, TPM1
37scn5a-related romano ward syndrome10.8MYH7, TPM1
38tpm2-related arthrogryposis multiplex congenita, distal, type 2b10.8MYH7, TPM1
39hyalinosis systemic short stature10.8MYH6, MYH7
40cerebellar vermis aplasia with associated features suggesting smith-lemli-opitz syndrome and meckel syndrome10.8ACTN2, CSRP3, MYH7
41craniosynostosis10.7MYH6, MYH7, TNNI3, TNNT2
42muscular dystrophy, rigid spine, 110.7MYH7, TTN
43cardiomyopathy, dilated, 1e10.7MYH7, TPM1
44charcot-marie-tooth hereditary neuropathy10.7CAV3, MYH6, MYH7, MYLK2
45symmastia10.7MYH7, TTN
46atrial standstill, digenic10.7ACTN2, MYBPC3, MYH7, MYL3, TNNI3, TNNT2
47meige syndrome10.7ACTC1, MYBPC3, MYH7, MYL3, TNNI3, TNNT2
48usher syndrome10.6ACTN2, CALR3, TTN
49immunodeficiency 34, mycobacteriosis, x-linked10.5CAV3, TNNI3, TTN
50rippling muscle disease10.5CAV3, TTN

Graphical network of the top 20 diseases related to Cardiomyopathy, Familial Hypertrophic:



Diseases related to cardiomyopathy, familial hypertrophic

Symptoms & Phenotypes for Cardiomyopathy, Familial Hypertrophic

About this section

Symptoms by clinical synopsis from OMIM:

192600

Clinical features from OMIM:

192600

Human phenotypes related to Cardiomyopathy, Familial Hypertrophic:

 64
id Description HPO Frequency HPO Source Accession
1 congestive heart failure64 HP:0001635
2 asymmetric septal hypertrophy64 HP:0001670
3 subaortic stenosis64 HP:0001682
4 abnormality of metabolism/homeostasis64 HP:0001939
5 arrhythmia64 HP:0011675

MGI Mouse Phenotypes related to Cardiomyopathy, Familial Hypertrophic according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538510.2ACTC1, CAV3, CSRP3, JPH2, MYBPC3, MYH6
2MP:00053699.4ACTC1, CAV3, CSRP3, JPH2, MYBPC3, MYH6

Drugs & Therapeutics for Cardiomyopathy, Familial Hypertrophic

About this section

Drugs for Cardiomyopathy, Familial Hypertrophic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 116)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
SpironolactoneapprovedPhase 42221952-01-7, 52-01-75833
Synonyms:
4-18-00-01601 (Beilstein Handbook Reference)
4-Pregnen-21-oic acid-17alpha-ol-3-one-7alpha-thiol gamma-lactone 7-acetate
496916-40-6
52-01-7
7-alpha-Acetylthio-3-oxo-17-alpha-pregn-4-ene-21,17-beta-carbolactone
7alpha-(acetylsulfanyl)-3-oxo-17alpha-pregn-4-ene-21,17-carbolactone
AB00513806
AC-4214
AC1L1L8Q
Abbolactone
Acelat
Aldace
Aldactazide
Aldactide
Aldactone
Aldactone (TN)
Aldactone A
Alderon
Aldopur
Almatol
Alphapharm Brand of Spironolactone
Alpharma Brand of Spironolactone
Alter Brand of Spironolactone
Altex
Aquareduct
Ashbourne Brand of Spironolactone
Azupharma Brand of Spironolactone
BIDD:PXR0071
BPBio1_000194
BRD-K90027355-001-03-4
BRN 0057767
BSPBio_000176
C07310
C24H32O4S
CHEBI:428201
CHEBI:45692
CHEBI:9241
CHEMBL1393
CID5833
CPD000471892
Cardel Brand of Spironolactone
D00443
D013148
DB00421
Deverol
Dexo Brand of Spironolactone
Diatensec
Dira
Duraspiron
EINECS 200-133-6
Espironolactona
Espironolactona Alter
Espironolactona Mundogen
Espironolactona [INN-Spanish]
Euteberol
Flumach
Frumikal
Generosan Brand of Spironolactone
HMS1568I18
HMS2090N21
HSDB 3184
Hormosan Brand of Spironolactone
I06-1970
Jenapharm Brand of Spironolactone
Jenaspiron
LS-118614
LT00772287
Lacalmin
Lacdene
Laractone
MLS001074672
MLS001333253
MLS001333254
MLS002153245
MLS002207058
Mayoly-Spindler Brand of Spironolactone
Melarcon
Merck dura Brand of Spironolactone
Mundogen Brand of Spironolactone
NCGC00164397-01
 
NCGC00164397-02
NSC 150399
NSC150399
Nefurofan
Novo Spiroton
Novo-Spiroton
NovoSpiroton
Novopharm Brand of Spironolactone
Osyrol
Pfizer Brand of Spironolactone
Pharmafrid Brand of Spironolactone
Practon
Prestwick0_000128
Prestwick1_000128
Prestwick2_000128
Prestwick3_000128
Roche Brand of Spironolactone
S0260
S3378_SIGMA
SAM002264648
SC 9420
SC-9420
SC9420
SMR000471892
SNL
SPBio_002115
Sagisal
Searle Brand of Spironolactone
Sincomen
Spiractin
Spiresis
Spiretic
Spiridon
Spiro L.U.T.
Spiro(17H-cyclopenta(a)phenauthrene-17,2'-(3'H)-furan)
Spiro-Tablinen
Spiro[17H-cyclopenta[a]phenauthrene-17,2'-(3'H)-furan]
Spirobeta
Spiroctan
Spiroctanie
Spiroderm
Spirogamma
Spirolactone
Spirolakton
Spirolang
Spirolone
Spirone
Spirono Isis
Spirono-Isis
Spironocompren
Spironolactone
Spironolactone (JP15/USP/INN)
Spironolactone A
Spironolactone [BAN:INN:JAN]
Spironolactone [INN:BAN:JAN]
Spironolactonum
Spironolactonum [INN-Latin]
Spironolattone
Spironolattone [DCIT]
Spironone
Spirospare
Sprioderm
Supra-puren
Suracton
UNII-27O7W4T232
Uractone
Urusonin
Veroshpiron
Verospiron
Verospirone
Verospirone Opianin
WLN: L E5 B666 FX OV MUTJ A1 E1 KSV1 F-& CT5VOXTJ
Worwag Brand of Spironolactone
Xenalon
ZINC03861599
betapharm Brand of Spironolactone
ct Arzneimittel Brand of Spironolactone
ct-Arzneimittel Brand of Spironolactone
spiro von ct
spironolactone
spironolattone
von ct, spiro
2
DobutamineapprovedPhase 411434368-04-236811
Synonyms:
(+-)-4-(2-((3-(P-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
(+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
34368-04-2
34368-04-2 (Parent)
4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol
4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
52663-81-7 (hydrochloride)
74753-15-4
74753-15-4 (hydrobromide)
AC1L1WFF
AC1Q7AD1
BPBio1_000489
BRD-A78322124-003-03-3
BSPBio_000443
C06967
CHEBI:4670
CHEMBL926
CID36811
D03879
DB00841
DL-Dobutamine
DL-dobutamine
Dobutamin
Dobutamina
Dobutamina [INN-Spanish]
Dobutamine
Dobutamine (USP/INN)
Dobutamine Hcl
Dobutamine Hcl in Dextrose 5%
 
Dobutamine Hydrochloride
Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer
Dobutamine [USAN:BAN:INN]
Dobutamine [USAN]
Dobutamine [Usan:Ban:Inn]
Dobutamine [Usan]
Dobutamine hydrobromide
Dobutaminum
Dobutaminum [INN-Latin]
Dobutrex
EINECS 277-982-4
HMS2089K05
Inotrex
L001157
LS-174467
LY 81929
Lilly 81929
Lopac0_000365
NCGC00015321-05
NCGC00024629-02
NCGC00024629-03
Prestwick0_000352
Prestwick1_000352
Prestwick2_000352
Prestwick3_000352
Racemic-Dobutamine
Racemic-dobutamine
SPBio_002364
UNII-0WR771DJXV
UNII-3S12J47372
dobutamine
dobutamine(usp)
rac-Dobutamine
rac-dobutamine
racemic-Dobutamine
3
Ranolazineapproved, investigationalPhase 478142387-99-3, 95635-55-556959
Synonyms:
( -)-Ranolazine
(-)-Ranolazine
142387-99-3
95635-55-5
AC-1673
AC1L1M17
AC1Q5LYD
BRD-A97674275-001-01-9
BSPBio_002276
CHEMBL1404
CID56959
CVT-303
D05700
DB00243
HMS1922F16
HMS2090L09
HMS2093D21
I01-2008
I06-0160
KEG-1295
LS-187267
Latixa
Lopac0_001062
 
MLS002154149
MolPort-003-666-653
N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
NCGC00015897-05
NCGC00095177-01
NCGC00095177-02
NCGC00095177-03
RAN D
RANOLAZINE
RS-43285
RS-43285-003
Ran4
Ranexa
Ranexa (TN)
Ranexa, Ranolazine
Ranolazine (USAN/INN)
Ranolazine 2HCl
Ranolazine Dihydrochloride
Ranolazine dihydrochloride
S1799_Selleck
SMR000857382
SPECTRUM1505366
UNII-A6IEZ5M406
ranolazine
4
Carvedilolapproved, investigationalPhase 416372956-09-32585
Synonyms:
(+-)-1-(Carbazol-4-yloxy)-3-((2-(O-methoxyphenoxy)ethyl)amino)-2-propanol
(+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+-)-1-Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol
(+/-)-1-(Carbazol-4-yloxy)-3-[[2-(o-methoxyphenoxy)ethyl]amino]-2-propanol
1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol
1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol
1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol
107741-96-8
72956-09-3
AB1004830
AC-1641
AC1L1E0B
Artist
Artist (TN)
Atlana Pharma brand of carvedilol
BM 14190
BM-14-190
BM-14.190
BM-14190
BRD-A10977446-001-04-8
BRD-A10977446-045-01-1
Bio-0014
C043211
C06875
C2260
C24H26N2O4
CHEBI:3441
CHEMBL723
CID2585
CPD000449280
Carvedilol
Carvedilol (JAN/USAN/INN)
Carvedilol [USAN:INN:BAN:JAN]
Carvedilolum
Carvedilolum [Latin]
Coreg
Coreg (TN)
Coreg CR
Coropres
Coropress
D00255
DB01136
DQ 2466
DQ-2466
Dibloc
 
Dilatrend
EG-P042
Eucardic
GlaxoSmithKline brand of carvedilol
HMS2051N03
HMS2089B09
HMS2093E12
HSDB 7044
I06-0064
I06-1477
KBio2_002145
KBio2_004713
KBio2_007281
KBio3_002323
KBioGR_001252
KBioSS_002145
Kredex
L001243
LS-121875
Lakeside brand of carvedilol
MLS000758299
MLS000759508
MLS001424092
MolPort-003-666-814
NCGC00167832-01
NCGC00167832-02
NCGC00167832-03
Querto
Roche brand of carvedilol
SAM001246736
SAM001247021
SK&F-105517
SKF 105517
SMR000449280
SPBio_001885
STK621453
Spectrum2_001673
Spectrum3_001182
Spectrum4_000636
Spectrum5_001436
Spectrum_001665
TL8005080
UNII-0K47UL67F2
carvedilol
carvedilol, (+-)-isomer
carvedilol, (R)-isomer
carvedilol, (S)-isomer
carvedilol, 14C-labeled
5
Metoprololapproved, investigationalPhase 420137350-58-6, 51384-51-14171
Synonyms:
(+/-)-Metoprolol
(RS)-Metoprolol
1-(Isopropylamino)-3-(4-(2-methoxyethyl)phenoxy)propan-2-ol
1-(Isopropylamino)-3-(p-(2-methoxyethyl)phenoxy)-2-propanol
1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol
1-[4-(2-methoxyethyl)phenoxy]-3-propan-2-ylamino-propan-2-ol
3-[4-(2-methoxyethyl)phenoxy]-1-(propan-2-ylamino)propan-2-ol
37350-58-6
51384-51-1
54163-88-1
AB00053499
AC-19022
AC1L1HKM
AstraZeneca Brand of Metaoprolol Tartrate
AstraZeneca Brand of Seloken
BRD-A03623303-045-02-0
Beatrolol
Beloc
Beloc Duriles
Beloc-Duriles
BelocDuriles
Betaloc
Betaloc Astra
Betaloc-Astra
BetalocAstra
Betalok
C07202
CCRIS 4198
CGP 2175
CGP-2175
CGP2175
CHEBI:6904
CHEMBL13
CID4171
D008790
D02358
DB00264
DL-metoprolol
Dl-Metoprolol
Dutoprol
EINECS 253-483-7
EINECS 257-166-4
H 93 26
H 93-26
H 9326
 
HMS2090B15
HSDB 6531
I01-7125
I06-0125
Jsp006606
L000669
LOPRESSIDONE
LS-122450
Leiras Brand of Metoprolol Succinate or Metoprolol Tartrate
Lopresor
Lopresoretic
Lopressor
Lopressor HCT
Meijoprolol
Metohexal
Metoprolol
Metoprolol (USAN/INN)
Metoprolol Tartrate
Metoprolol [USAN:INN:BAN]
Metoprolol slow release
Metoprolol succinate
Metoprolol tartrate
Metoprololum
Metoprololum [INN-Latin]
Metroprolol
MolPort-005-938-039
NCGC00021148-02
NCGC00021148-03
NCGC00021148-04
Novartis Brand of Metprolol Tartrate
Preblok
Prelis
Presolol
Selo-Zok
Seloken
Seloken AstraZeneca Brand
Selopral
Seroken
Spesicor
Spesikor
TOPROL-XL
Tartrate, Metoprolol
Toprol
Toprol XL
Toprol-XL
UNII-GEB06NHM23
dl-Metoprolol
metoprolol
6
DoxazosinapprovedPhase 45774191-85-83157
Synonyms:
1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-[4-(1,4-benzodioxan-2-yl)carpiperazin-1-yl)]-6,7-dimethoxyquinazoline mesylate
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine
2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
2-{4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazin-1-yl}-6,7-dimethoxyquinazolin-4-amine
74191-85-8
77883-43-3 (mesylate)
AC-11062
AC1L1FAT
AC1Q470P
AC1Q4EXN
AKOS001681453
BPBio1_000963
BRD-A13188892-066-03-3
BSPBio_000875
C06970
C23H25N5O5
CHEBI:4708
CHEMBL707
CID3157
CPD000097306
Cardura XL (TN)
Cardura-1
Cardura-2
Cardura-4
ChemDiv2_005017
D07874
D9815_SIGMA
DB00590
 
Doxazosin (INN)
Doxazosin [INN:BAN]
Doxazosin mesilate
Doxazosina
Doxazosina [Spanish]
Doxazosine
Doxazosine [French]
Doxazosinum
Doxazosinum [Latin]
HMS1383E01
HMS2090C20
I06-1346
IDI1_003732
L000738
LS-110228
Lopac0_000474
MolPort-001-684-491
NCGC00018158-06
NCGC00089775-02
Normothen
Oprea1_259518
Prestwick0_000858
Prestwick1_000858
Prestwick2_000858
Prestwick3_000858
SAM002589981
SPBio_002796
UK 33274
UK-33274
UNII-NW1291F1W8
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone
doxazosin
7
ChlorthalidoneapprovedPhase 46377-36-12732
Synonyms:
(+-)-Chlorthalidone
(+-)-Hygroton
1-Keto-3-(3'-sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-Oxo-3-(3-sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
1-keto-3-(3'-Sulfamyl-4'-chlorophenyl)-3-hydroxyisoindoline
1-oxo-3-(3-Sulfamyl-4-chlorophenyl)-3-hydroxyisoindoline
2-Chloro-5-(1-hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
2-Chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide
2-chloro-5-(1-Hydroxy-3-oxo-1-isoindolinyl)benzenesulfonamide
2-chloro-5-(1-hydroxy-3-oxo-2H-isoindol-1-yl)benzenesulfonamide
2-chloro-5-(2,3-dihydro-1-Hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide
2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide
3-(4'-Chloro-3'-sulfamoylphenyl)-3-hydroxyphthalimidine
3-(4'-chloro-3'-Sulfamoylphenyl)-3-hydroxyphthalimidine
3-Hydroxy-3-(4-chloro-3-sulfamylphenyl)phthalimidine
5-22-07-00602 (Beilstein Handbook Reference)
77-36-1
A3836/0162845
AB00051946
AC-11367
AC1L1ECB
AC1Q558X
BPBio1_000487
BRD-A26384407-001-05-3
BRN 0312295
BSPBio_000441
BSPBio_002017
C14H11ClN2O4S
C2775_FLUKA
C2775_SIGMA
CHEBI:3654
CHEMBL1055
CID2732
CPD000058635
Chlorothalidone
Chlorphthalidolone
Chlorphthalidone
Chlortalidone
Chlortalidone (JAN/INN)
Chlortalidonum
Chlortalidonum [INN-Latin]
Chlorthalidon
Chlorthalidone
Chlorthalidone (USP)
Chlorthalidone [USAN:INN:BAN]
Clodronic Acid
Clortalidona
Clortalidona [INN-Spanish]
Clortalidone
Clortalidone [DCIT]
D00272
D002752
DB00310
DivK1c_000731
EINECS 201-022-5
Famolin
G 33182
G-33182
HMS1569G03
HMS1920M09
 
HMS2091E12
HMS502E13
HSDB 3035
Higroton
Hydro-Long
Hygroton
Hygroton (TN)
I06-0208
IDI1_000731
Igroton
Isoren
KBio1_000731
KBio2_000626
KBio2_003194
KBio2_005762
KBio3_001237
KBioGR_001574
KBioSS_000626
LS-31408
MLS000069531
MolPort-002-736-049
NCGC00094616-01
NCGC00094616-02
NCGC00094616-03
NCGC00094616-04
NINDS_000731
NSC 69200
NSC69200
Natriuran
Oksodolin (oxodolin)
Oradil
Oxodolin
Oxodoline
Phthalamodine
Phthalamudine
Prestwick0_000351
Prestwick1_000351
Prestwick2_000351
Prestwick3_000351
Prestwick_759
Racemic chlorthalidone
Renon
SAM002589983
SMR000058635
SPBio_000058
SPBio_002362
SPECTRUM1500187
ST088141
STK686335
Saluretin
Spectrum2_000099
Spectrum3_000349
Spectrum4_000957
Spectrum5_000743
Spectrum_000146
Tenoretic
Thalitone
Thalitone (TN)
UNII-Q0MQD1073Q
Urolin
Zambesil
chlorthalidone
8
Tadalafilapproved, investigationalPhase 4, Phase 2149171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
9
GlimepirideapprovedPhase 423093479-97-13476
Synonyms:
1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea
1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea
3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
64598P
93479-97-1
AB00513874
AC-476
AC1L1G0T
Amarel
Amaryl
Amaryl (TN)
Amaryl, Glista OD, Glimepiride
Avaglim
BPBio1_000751
BRD-K34776109-001-03-4
BRD-K42693031-001-01-8
BRN 5365754
BSPBio_000681
Bio-0049
C07669
C24H34N4O5S
CAS-93479-97-1
CCRIS 7083
CHEBI:5383
CHEMBL1481
CID3476
CPD000466368
D00593
DB00222
Endial
G2295_SIGMA
Glimepirid
Glimepirida
Glimepirida [Spanish]
Glimepiride (JAN/USP/INN)
Glimepiride [USAN:BAN:INN]
Glimepiridum
Glimepiridum [Latin]
 
Glimepride
Glimer
Glimépiride
Glymepirid
HMS1570C03
HMS2052L03
HMS2090K18
HOE 490
Hoe-490
I06-0029
I06-2285
LS-136752
MLS000759495
MLS001076674
MLS001401419
MolPort-003-847-587
MolPort-003-987-461
MolPort-005-941-721
NCGC00016960-01
NCGC00161404-01
NCGC00161404-02
NCGC00181757-01
Novo-glimepiride
Oprea1_382896
PMS-glimepiride
Prestwick0_000651
Prestwick1_000651
Prestwick2_000651
Prestwick3_000651
Ratio-glimepiride
Roname
S1344_Selleck
SAM001246710
SMR000466368
SPBio_002602
Sandoz glimepiride
Solosa
TL8005924
UNII-6KY687524K
ZINC00537791
glimepiride
10
EmpagliflozinapprovedPhase 4113864070-44-0
Synonyms:
 
(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
11Antihypertensive AgentsPhase 4, Phase 2, Phase 34095
12Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 412767
13HormonesPhase 4, Phase 113979
14Diuretics, Potassium SparingPhase 41827
15Hormone AntagonistsPhase 412778
16Calcium, DietaryPhase 4, Phase 2, Phase 35525
17Vasodilator AgentsPhase 4, Phase 2, Phase 33438
18MineralocorticoidsPhase 4352
19diureticsPhase 41372
20Natriuretic AgentsPhase 4, Phase 11645
21Mineralocorticoid Receptor AntagonistsPhase 4333
22Atorvastatin CalciumPhase 4, Phase 3743134523-03-8
23AntimetabolitesPhase 4, Phase 311774
24Hydroxymethylglutaryl-CoA Reductase InhibitorsPhase 4, Phase 31956
25Immunosuppressive AgentsPhase 4, Phase 212770
26Adrenergic beta-AgonistsPhase 41640
27Protective AgentsPhase 4, Phase 17190
28Adrenergic AgonistsPhase 42877
29Anticholesteremic AgentsPhase 4, Phase 31983
30Lipid Regulating AgentsPhase 4, Phase 32702
31Hypolipidemic AgentsPhase 4, Phase 32721
32Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 222776
33Adrenergic alpha-AntagonistsPhase 4727
34Adrenergic AntagonistsPhase 4, Phase 31535
35Adrenergic alpha-1 Receptor AntagonistsPhase 4470
36Adrenergic AgentsPhase 4, Phase 35140
37Sodium Channel BlockersPhase 41515
38Adrenergic beta-AntagonistsPhase 4, Phase 31154
39Adrenergic beta-1 Receptor AntagonistsPhase 4, Phase 3350
40SympatholyticsPhase 4, Phase 3555
41Autonomic AgentsPhase 4, Phase 39774
42Neurotransmitter AgentsPhase 4, Phase 317734
43Anti-Arrhythmia AgentsPhase 4, Phase 3, Phase 22969
44Phosphodiesterase 5 InhibitorsPhase 4, Phase 2571
45Sodium Chloride Symporter InhibitorsPhase 4446
46Phosphodiesterase InhibitorsPhase 4, Phase 21254
47Hypoglycemic AgentsPhase 45733
48carnitineNutraceuticalPhase 4, Phase 2158
49
PerhexilineapprovedPhase 2, Phase 386621-47-24746
Synonyms:
(+)-2-(2,2-Dicyclohexylethyl)piperidine
(-)-2-(2,2-Dicyclohexylethyl)piperidine
2-(2,2-Dicyclohexylethyl)piperidine
39648-47-0
39648-48-1
6621-47-2
AB00053656
AC1L1IV5
BPBio1_000212
BSPBio_000192
BSPBio_003118
C19H35N
CHEBI:35553
CHEMBL75880
CID4746
D010480
D08340
DB01074
DivK1c_000542
EINECS 229-569-5
EINECS 254-558-7
EINECS 254-559-2
IDI1_000542
KBio1_000542
KBio2_000353
KBio2_002921
KBio2_005489
 
KBio3_002618
KBioGR_000685
KBioSS_000353
LS-176505
MolPort-003-808-309
NINDS_000542
Oprea1_365504
PERHEXILINE
Perhexilene
Perhexilina
Perhexilina [INN-Spanish]
Perhexiline
Perhexiline (INN)
Perhexiline [INN:BAN]
Perhexilinum
Perhexilinum [INN-Latin]
Perhexilline
Prestwick0_000286
Prestwick1_000286
Prestwick2_000286
Prestwick3_000286
SPBio_001358
SPBio_002411
Spectrum2_001539
Spectrum3_001579
Spectrum4_000173
Spectrum5_001084
Spectrum_000013
perhexilline
50
EthanolapprovedPhase 3, Phase 2204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol

Interventional clinical trials:

(show top 50)    (show all 146)
idNameStatusNCT IDPhase
1Clinical and Therapeutic Implications of Fibrosis in Hypertrophic CardiomyopathyUnknown statusNCT00879060Phase 4
2Identification of Carnitine-Responsive CardiomyopathyUnknown statusNCT01904396Phase 4
3Effects of Spironolactone in DialysisUnknown statusNCT01128101Phase 4
4Ranolazine for the Treatment of Chest Pain in HCM PatientsCompletedNCT01721967Phase 4
5Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human HeartCompletedNCT01798992Phase 4
6Assessment of Wall Thickness in Hypertrophic CardiomyopathyRecruitingNCT02234336Phase 4
7REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrsRecruitingNCT01803828Phase 4
8Effects of Atorvastatin Treatment on Left Ventricular Diastolic Function in Peritoneal Dialysis PatientsRecruitingNCT01503671Phase 4
9Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKDRecruitingNCT02502981Phase 4
10Evaluating the Effect of Spironolactone on Hypertrophic CardiomyopathyNot yet recruitingNCT02948998Phase 4
11SGLT2 Inhibition and Left Ventricular MassNot yet recruitingNCT02728453Phase 4
12The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve ReplacementSuspendedNCT01375335Phase 4
13Aortic Stenosis and PhosphodiEsterase iNhibition With Aortic Valve Replacement (ASPEN-AVR): A Pilot StudyTerminatedNCT01272388Phase 4
14Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic CardiomyopathyUnknown statusNCT00698074Phase 3
15Myocardial Protection With Perhexiline in Left Ventricular HypertrophyUnknown statusNCT00989508Phase 2, Phase 3
16Treatment of Preclinical Hypertrophic Cardiomyopathy With DiltiazemCompletedNCT00319982Phase 2, Phase 3
17Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic CardiomyopathyCompletedNCT00821353Phase 3
18Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the HeartCompletedNCT00317967Phase 3
19Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan SyndromeCompletedNCT00723801Phase 3
20Mobilization of Endothelial Progenitor Cells and AspirinRecruitingNCT02674958Phase 3
21Lung Water by Ultrasound Guided Treatment in Hemodialysis Patients (The Lust Study).RecruitingNCT02310061Phase 3
22Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic CardiomyopathyActive, not recruitingNCT02291237Phase 2, Phase 3
23Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart FailureNot yet recruitingNCT02431221Phase 3
24The PARTNER 3 - AVIV TrialNot yet recruitingNCT03003299Phase 3
25Trimetazidine Therapy in Hypertrophic CardiomyopathyUnknown statusNCT01696370Phase 2
26CHANCE - Candesartan in Hypertrophic CardiomyopathyUnknown statusNCT00430833Phase 2
27Perhexiline Therapy in Patients With Hypertrophic CardiomyopathyCompletedNCT00500552Phase 2
28Inhibition of the Renin Angiotensin System With Losartan in Patients With Hypertrophic CardiomyopathyCompletedNCT01447654Phase 2
29Pirfenidone to Treat Hypertrophic CardiomyopathyCompletedNCT00011076Phase 2
30Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot StudyCompletedNCT00035386Phase 2
31A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic CardiomyopathyCompletedNCT00001894Phase 2
32Effect of Losartan in Patients With Nonobstructive Hypertrophic CardiomyopathyCompletedNCT01150461Phase 2
33Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)CompletedNCT00001965Phase 2
34Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart MuscleCompletedNCT00001960Phase 2
35Study of Blood Flow in Heart MuscleCompletedNCT00001631Phase 2
36Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart FailureRecruitingNCT02862600Phase 2
37A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract ObstructionRecruitingNCT02842242Phase 2
38CArdiac Desynchronization In Obstructive HCM, CARDIO-HCMRecruitingNCT01332162Phase 2
39Hypertrophic Cardiomyopathy Symptom Release by BX1514MRecruitingNCT02590809Phase 2
40Study to Develop a Non-invasive Marker for Monitoring Myocardial FibrosisRecruitingNCT01230918Phase 2
41Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCMRecruitingNCT01912534Phase 2
42Renal Nerve Stimulation and Renal Denervation in Patients With Sympathetic Ventricular ArrhythmiasRecruitingNCT02856373Phase 2
43Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly CardiomyopathyNot yet recruitingNCT02611336Phase 2
44Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrsNot yet recruitingNCT02611258Phase 2
45Feasibility Study of Radiofrequency Heating of Cardiac Infarction Scar to Treat Heart FailureTerminatedNCT00881777Phase 1, Phase 2
46Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic CardiomyopathyWithdrawnNCT01556568Phase 2
47Biventricular Pacing in Hypertrophic CardiomyopathyUnknown statusNCT00504647Phase 1
48BNP Testing in Patients With SOB on Presentation to EDUnknown statusNCT00163709Phase 1
49Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...CompletedNCT00001396Phase 1
50Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461CompletedNCT02329184Phase 1

Search NIH Clinical Center for Cardiomyopathy, Familial Hypertrophic


Cochrane evidence based reviews: cardiomyopathy, hypertrophic, familial

Genetic Tests for Cardiomyopathy, Familial Hypertrophic

About this section

Genetic tests related to Cardiomyopathy, Familial Hypertrophic:

id Genetic test Affiliating Genes
1 Familial Hypertrophic Cardiomyopathy 127
2 Hypertrophic Cardiomyopathy27
3 Asymmetric Septal Hypertrophy27
4 Familial Hypertrophic Cardiomyopathy24 TTN

Anatomical Context for Cardiomyopathy, Familial Hypertrophic

About this section

MalaCards organs/tissues related to Cardiomyopathy, Familial Hypertrophic:

36
Heart, Testes, Endothelial, Breast, Lung, Skeletal muscle, Brain

Publications for Cardiomyopathy, Familial Hypertrophic

About this section

Variations for Cardiomyopathy, Familial Hypertrophic

About this section

UniProtKB/Swiss-Prot genetic disease variations for Cardiomyopathy, Familial Hypertrophic:

70 (show all 174)
id Symbol AA change Variation ID SNP ID
1CAV3p.Thr64SerVAR_029543rs121909280
2MYH7p.Ala26ValVAR_004566rs186964570
3MYH7p.Val59IleVAR_004567rs771132107
4MYH7p.Arg143GlnVAR_004568rs397516209
5MYH7p.Arg249GlnVAR_004569rs3218713
6MYH7p.Gly256GluVAR_004570rs121913633
7MYH7p.Ile263ThrVAR_004571rs397516269
8MYH7p.Met349ThrVAR_004572rs121913640
9MYH7p.Arg403LeuVAR_004573rs121913624
10MYH7p.Arg403GlnVAR_004574rs121913624
11MYH7p.Arg403TrpVAR_004575rs3218714
12MYH7p.Arg453CysVAR_004576rs121913625
13MYH7p.Phe513CysVAR_004577rs121913636
14MYH7p.Gly584ArgVAR_004578rs121913626
15MYH7p.Asp587ValVAR_004579
16MYH7p.Asn602SerVAR_004580rs730880880
17MYH7p.Val606MetVAR_004581rs121913627
18MYH7p.Lys615AsnVAR_004582
19MYH7p.Gly716ArgVAR_004583rs121913638
20MYH7p.Arg719TrpVAR_004584rs121913637
21MYH7p.Arg723CysVAR_004585rs121913630
22MYH7p.Pro731LeuVAR_004586
23MYH7p.Ile736MetVAR_004587
24MYH7p.Gly741ArgVAR_004588rs121913632
25MYH7p.Gly741TrpVAR_004589rs121913632
26MYH7p.Asp778GlyVAR_004590rs121913634
27MYH7p.Ala797ThrVAR_004591rs3218716
28MYH7p.Arg870HisVAR_004592rs36211715
29MYH7p.Leu908ValVAR_004593rs121913631
30MYH7p.Glu924LysVAR_004594rs121913628
31MYH7p.Glu930LysVAR_004595rs397516171
32MYH7p.Glu935LysVAR_004597rs121913639
33MYH7p.Glu949LysVAR_004598rs121913629
34MYH7p.Glu743AspVAR_014199rs397516139
35MYH7p.Arg719GlnVAR_017749rs121913641
36MYH7p.Ala728ValVAR_017750rs121913644
37MYH7p.Val39MetVAR_019845rs376160714
38MYH7p.Thr188AsnVAR_019846rs730880844
39MYH7p.Arg204HisVAR_019847rs397516260
40MYH7p.Asn232SerVAR_019848
41MYH7p.Ala355ThrVAR_019849rs397516088
42MYH7p.Ala428ValVAR_019850rs727503266
43MYH7p.Ile443ThrVAR_019851
44MYH7p.Asn479SerVAR_019852rs727504236
45MYH7p.Glu483LysVAR_019853rs121913651
46MYH7p.Met659IleVAR_019854
47MYH7p.Arg663HisVAR_019855rs371898076
48MYH7p.Arg663SerVAR_019856
49MYH7p.Arg671CysVAR_019857rs727503263
50MYH7p.Gly733GluVAR_019858rs727504241
51MYH7p.Gly768ArgVAR_019859rs727503260
52MYH7p.Asp778GluVAR_019860rs2069544
53MYH7p.Arg787HisVAR_019861rs376754645
54MYH7p.Met852ThrVAR_019862rs397516157
55MYH7p.Arg869GlyVAR_019863
56MYH7p.Leu1135ArgVAR_019865
57MYH7p.Glu1218GlnVAR_019866
58MYH7p.Thr1377MetVAR_019867rs397516201
59MYH7p.Ala1379ThrVAR_019868rs397516202
60MYH7p.Arg1382TrpVAR_019869rs730880910
61MYH7p.Ala1777ThrVAR_019871rs200939753
62MYH7p.Thr124IleVAR_020797
63MYH7p.Tyr162CysVAR_020798
64MYH7p.Asn187LysVAR_020799
65MYH7p.Arg190ThrVAR_020800
66MYH7p.Gln222LysVAR_020801
67MYH7p.Phe244LeuVAR_020802rs730880849
68MYH7p.Val320MetVAR_020803rs376897125
69MYH7p.Leu390ValVAR_020804
70MYH7p.Val406MetVAR_020805
71MYH7p.Glu499LysVAR_020806rs3218715
72MYH7p.Gln595ArgVAR_020807
73MYH7p.Leu601ValVAR_020808
74MYH7p.Arg694CysVAR_020809rs727504240
75MYH7p.Asn696SerVAR_020810rs730880732
76MYH7p.Arg712LeuVAR_020811
77MYH7p.Arg723GlyVAR_020812rs121913630
78MYH7p.Ser782AsnVAR_020813
79MYH7p.Glu846GlnVAR_020814rs730880748
80MYH7p.Arg869CysVAR_020815rs730880750
81MYH7p.Arg870CysVAR_020816rs36211715
82MYH7p.Met877LysVAR_020817
83MYH7p.Glu1555LysVAR_020820
84MYH7p.Ser1776GlyVAR_020821rs369437262
85MYH7p.Arg143TrpVAR_029431rs727503278
86MYH7p.Val411IleVAR_029432rs730880868
87MYH7p.Ala430GluVAR_029433
88MYH7p.Leu517MetVAR_029435rs727504237
89MYH7p.Gly584SerVAR_029436rs121913626
90MYH7p.Arg694HisVAR_029437
91MYH7p.Gln734GluVAR_029438
92MYH7p.Ile736ThrVAR_029439rs727503261
93MYH7p.Leu796PheVAR_029440
94MYH7p.Val824IleVAR_029441
95MYH7p.Cys905PheVAR_029442
96MYH7p.Glu924GlnVAR_029443
97MYH7p.Asp928AsnVAR_029444rs727503252
98MYH7p.Met515ValVAR_039562
99MYH7p.Arg858CysVAR_039563rs2754158
100MYH7p.Tyr115HisVAR_042762rs397516183
101MYH7p.Arg143GlyVAR_042763rs727503278
102MYH7p.Lys146AsnVAR_042764rs397516212
103MYH7p.Ser148IleVAR_042765rs772691929
104MYH7p.Val186LeuVAR_042766rs786205906
105MYH7p.Ala196ThrVAR_042767
106MYH7p.Lys207GlnVAR_042769rs727504273
107MYH7p.Pro211LeuVAR_042770rs727503277
108MYH7p.Leu227ValVAR_042771
109MYH7p.Ile263MetVAR_042772rs730880855
110MYH7p.Phe312CysVAR_042773
111MYH7p.Glu328GlyVAR_042774
112MYH7p.Lys351GluVAR_042775rs730880864
113MYH7p.Lys383AsnVAR_042776
114MYH7p.Ala385ValVAR_042777
115MYH7p.Val404LeuVAR_042778
116MYH7p.Val404MetVAR_042779rs730880867
117MYH7p.Gly407ValVAR_042780rs397516095
118MYH7p.Gly425ArgVAR_042782rs397516097
119MYH7p.Met435ThrVAR_042783
120MYH7p.Val440MetVAR_042784rs397516098
121MYH7p.Lys450GluVAR_042786
122MYH7p.Lys450ThrVAR_042787
123MYH7p.Arg453HisVAR_042788rs397516101
124MYH7p.Glu500AlaVAR_042789rs727504286
125MYH7p.Tyr501CysVAR_042790
126MYH7p.Ile511PheVAR_042791
127MYH7p.Ile511ThrVAR_042792rs397516110
128MYH7p.Met515ArgVAR_042793
129MYH7p.Gly571ArgVAR_042795rs730880879
130MYH7p.His576ArgVAR_042796rs727504238
131MYH7p.Lys615GlnVAR_042797
132MYH7p.Arg663CysVAR_042798rs397516127
133MYH7p.Val698AlaVAR_042799rs397516130
134MYH7p.Gln734ProVAR_042800rs863225097
135MYH7p.Ala742GluVAR_042801rs786205907
136MYH7p.Val763GlyVAR_042802rs730880735
137MYH7p.Glu774ValVAR_042803
138MYH7p.Asp778ValVAR_042804
139MYH7p.Met822LeuVAR_042805rs730880742
140MYH7p.Met822ThrVAR_042806
141MYH7p.Gly823GluVAR_042807
142MYH7p.Arg858HisVAR_042809rs2856897
143MYH7p.Arg869HisVAR_042810rs202141173
144MYH7p.Gln882GluVAR_042811rs397516160
145MYH7p.Glu894GlyVAR_042812rs397516161
146MYH7p.Ala901GlyVAR_042813
147MYH7p.Asp906GlyVAR_042814rs267606908
148MYH7p.Glu921LysVAR_042815rs730880759
149MYH7p.Glu927LysVAR_042816rs397516170
150MYH7p.Glu931LysVAR_042817
151MYH7p.Asp953HisVAR_042818
152MYH7p.Gly1057AspVAR_042820
153MYH7p.Gly1057SerVAR_042821rs397516179
154MYH7p.Asn1327LysVAR_042823rs141764279
155MYH7p.Glu1356LysVAR_042824rs727503246
156MYH7p.Arg1420TrpVAR_042825rs145213771
157MYH7p.Ala1454ThrVAR_042827
158MYH7p.Lys1459AsnVAR_042828rs201307101
159MYH7p.Thr1513SerVAR_042830rs397516222
160MYH7p.Arg1712TrpVAR_042834rs121913650
161MYH7p.Glu1753LysVAR_042836rs545585809
162MYH7p.Glu1768LysVAR_042837rs397516241
163MYH7p.Thr1854MetVAR_042838rs372381770
164MYH7p.Glu1883LysVAR_042839rs121913652
165MYH7p.Thr1929MetVAR_042842rs730880918
166MYH7p.Val763MetVAR_045926rs727504253
167MYH7p.Arg787CysVAR_045927rs145677314
168MYH7p.Leu1414MetVAR_045928rs201895208
169MYH7p.Glu1752LysVAR_072816rs730880916
170MYH7p.Arg243HisVAR_073876rs267606910
171MYH7p.Arg453SerVAR_073880rs121913625
172MYH7p.Glu497AspVAR_073881rs267606911
173MYLK2p.Ala87ValVAR_014197rs121908107
174MYLK2p.Ala95GluVAR_014198rs121908108

Clinvar genetic disease variations for Cardiomyopathy, Familial Hypertrophic:

5 (show all 134)
id Gene Variation Type Significance SNP ID Assembly Location
1TNNT2NM_000364.3(TNNT2): c.853C> T (p.Arg285Cys)SNVLikely pathogenic, Pathogenicrs121964857GRCh37Chr 1, 201328373: 201328373
2MYL3NM_000258.2(MYL3): c.445A> G (p.Met149Val)SNVPathogenicrs104893748GRCh37Chr 3, 46901001: 46901001
3MYL3NM_000258.2(MYL3): c.461G> A (p.Arg154His)SNVLikely pathogenic, Pathogenicrs104893749GRCh37Chr 3, 46900985: 46900985
4MYH7NM_000257.3(MYH7): c.1208G> A (p.Arg403Gln)SNVPathogenicrs121913624GRCh37Chr 14, 23898487: 23898487
5MYH7NM_000257.3(MYH7): c.746G> A (p.Arg249Gln)SNVLikely pathogenic, Pathogenicrs3218713GRCh37Chr 14, 23900677: 23900677
6MYH7NM_000257.3(MYH7): c.1357C> T (p.Arg453Cys)SNVLikely pathogenic, Pathogenicrs121913625GRCh37Chr 14, 23898214: 23898214
7MYH7NM_000257.3(MYH7): c.1750G> C (p.Gly584Arg)SNVLikely pathogenic, Pathogenicrs121913626GRCh37Chr 14, 23896932: 23896932
8MYH7NM_000257.3(MYH7): c.1816G> A (p.Val606Met)SNVLikely pathogenic, Pathogenicrs121913627GRCh37Chr 14, 23896866: 23896866
9MYH7NM_000257.3(MYH7): c.2770G> A (p.Glu924Lys)SNVLikely pathogenic, Pathogenicrs121913628GRCh37Chr 14, 23893268: 23893268
10MYH7NM_000257.3(MYH7): c.2845G> A (p.Glu949Lys)SNVPathogenicrs121913629GRCh37Chr 14, 23893193: 23893193
11MYH7NM_000257.3(MYH7): c.1046T> C (p.Met349Thr)SNVPathogenicrs121913640GRCh37Chr 14, 23899076: 23899076
12MYH7NM_000257.3(MYH7): c.2167C> T (p.Arg723Cys)SNVLikely pathogenic, Pathogenicrs121913630GRCh37Chr 14, 23895023: 23895023
13MYH7nsv513807deletionPathogenicChr na, -1: -1
14MYH7NM_000257.3(MYH7): c.2722C> G (p.Leu908Val)SNVLikely pathogenic, Pathogenicrs121913631GRCh37Chr 14, 23893316: 23893316
15MYH7NM_000257.3(MYH7): c.2221G> C (p.Gly741Arg)SNVLikely pathogenic, Pathogenicrs121913632GRCh37Chr 14, 23894969: 23894969
16MYH7NM_000257.3(MYH7): c.767G> A (p.Gly256Glu)SNVPathogenicrs121913633GRCh37Chr 14, 23900656: 23900656
17MYH7NM_000257.3(MYH7): c.2333A> G (p.Asp778Gly)SNVPathogenicrs121913634GRCh37Chr 14, 23894581: 23894581
18MYH7NM_000257.3(MYH7): c.1208G> T (p.Arg403Leu)SNVLikely pathogenic, Pathogenicrs121913624GRCh37Chr 14, 23898487: 23898487
19MYH7NM_000257.3(MYH7): c.1207C> T (p.Arg403Trp)SNVLikely pathogenic, Pathogenicrs3218714GRCh37Chr 14, 23898488: 23898488
20MYH7NM_000257.3(MYH7): c.1538T> G (p.Phe513Cys)SNVPathogenicrs121913636GRCh37Chr 14, 23897749: 23897749
21MYH7NM_000257.3(MYH7): c.2155C> T (p.Arg719Trp)SNVPathogenicrs121913637GRCh37Chr 14, 23895180: 23895180
22MYH7NM_000257.3(MYH7): c.2146G> A (p.Gly716Arg)SNVLikely pathogenic, Pathogenicrs121913638GRCh37Chr 14, 23895189: 23895189
23MYH7NM_000257.3(MYH7): c.2803G> A (p.Glu935Lys)SNVPathogenicrs121913639GRCh37Chr 14, 23893235: 23893235
24MYH7NM_000257.3(MYH7): c.2156G> A (p.Arg719Gln)SNVLikely pathogenic, Pathogenicrs121913641GRCh37Chr 14, 23895179: 23895179
25MYH7NM_000257.3(MYH7): c.2183C> T (p.Ala728Val)SNVPathogenicrs121913644GRCh37Chr 14, 23895007: 23895007
26MYH7NM_000257.3(MYH7): c.5134C> T (p.Arg1712Trp)SNVLikely pathogenic, Pathogenicrs121913650GRCh37Chr 14, 23884861: 23884861
27MYH7NM_000257.3(MYH7): c.1447G> A (p.Glu483Lys)SNVPathogenicrs121913651GRCh37Chr 14, 23897840: 23897840
28MYH7NM_000257.3(MYH7): c.2609G> A (p.Arg870His)SNVLikely pathogenic, Pathogenicrs36211715GRCh37Chr 14, 23894048: 23894048
29MYH7NM_000257.3(MYH7): c.1322C> T (p.Thr441Met)SNVPathogenicrs121913653GRCh37Chr 14, 23898249: 23898249
30MYH7NM_000257.3(MYH7): c.5378T> C (p.Leu1793Pro)SNVLikely pathogenic, Pathogenicrs121913654GRCh37Chr 14, 23884385: 23884385
31MYH7NM_000257.3(MYH7): c.1491G> T (p.Glu497Asp)SNVLikely pathogenic, Pathogenicrs267606911GRCh37Chr 14, 23897796: 23897796
32MYH7NM_000257.3(MYH7): c.2717A> G (p.Asp906Gly)SNVPathogenicrs267606908GRCh37Chr 14, 23893321: 23893321
33MYH7NM_000257.3(MYH7): c.728G> A (p.Arg243His)SNVPathogenicrs267606910GRCh37Chr 14, 23900798: 23900798
34MYH7NM_000257.3(MYH7): c.1357C> A (p.Arg453Ser)SNVPathogenicrs121913625GRCh37Chr 14, 23898214: 23898214
35MYBPC3NM_000256.3(MYBPC3): c.3190+5G> ASNVLikely pathogenic, Pathogenicrs587782958GRCh38Chr 11, 47333552: 47333552
36MYBPC3NM_000256.3(MYBPC3): c.3642G> A (p.Trp1214Ter)SNVLikely pathogenic, Pathogenicrs368765949GRCh37Chr 11, 47353795: 47353795
37MYBPC3NM_000256.3(MYBPC3): c.1484G> A (p.Arg495Gln)SNVLikely pathogenic, Pathogenicrs200411226GRCh37Chr 11, 47364269: 47364269
38MYH7NM_000257.3(MYH7): c.4498C> T (p.Arg1500Trp)SNVLikely pathogenic, Pathogenicrs45544633GRCh37Chr 14, 23886383: 23886383
39MYH7NM_000257.3(MYH7): c.2207T> C (p.Ile736Thr)SNVLikely pathogenic, Pathogenicrs727503261GRCh37Chr 14, 23894983: 23894983
40MYH7NM_000257.3(MYH7): c.1954A> G (p.Arg652Gly)SNVLikely pathogenic, Pathogenicrs727504239GRCh37Chr 14, 23896451: 23896451
41MYBPC3NM_000256.3(MYBPC3): c.2780_2781delCA (p.Thr927Ilefs)deletionPathogenicrs727504265GRCh37Chr 11, 47356717: 47356718
42MYH7NM_000257.3(MYH7): c.2221G> T (p.Gly741Trp)SNVLikely pathogenic, Pathogenicrs121913632GRCh37Chr 14, 23894969: 23894969
43MYBPC3NM_000256.3(MYBPC3): c.1210C> T (p.Gln404Ter)SNVPathogenicrs727504329GRCh37Chr 11, 47365056: 47365056
44MYBPC3NM_000256.3(MYBPC3): c.2394dupT (p.Gly799Trpfs)duplicationLikely pathogenic, Pathogenicrs730880341GRCh37Chr 11, 47359260: 47359260
45MYH7NM_000257.3(MYH7): c.1324C> T (p.Arg442Cys)SNVPathogenicrs148808089GRCh37Chr 14, 23898247: 23898247
46MYBPC3NM_000256.3(MYBPC3): c.1000G> A (p.Glu334Lys)SNVLikely pathogenic, Pathogenicrs573916965GRCh37Chr 11, 47367848: 47367848
47MYBPC3NM_000256.3(MYBPC3): c.1829A> T (p.Asp610Val)SNVPathogenicrs730880554GRCh38Chr 11, 47341206: 47341206
48MYBPC3NM_000256.3(MYBPC3): c.1595delG (p.Gly532Alafs)deletionPathogenicrs730880640GRCh38Chr 11, 47342607: 47342607
49MYBPC3NM_000256.3(MYBPC3): c.1838dupA (p.Asp613Glufs)duplicationLikely pathogenic, Pathogenicrs730880649GRCh37Chr 11, 47362748: 47362748
50MYBPC3NM_000256.3(MYBPC3): c.1028delC (p.Thr343Metfs)deletionPathogenicrs730880686GRCh38Chr 11, 47346269: 47346269
51MYH7NM_000257.3(MYH7): c.2191C> T (p.Pro731Ser)SNVLikely pathogenic, Pathogenicrs727504299GRCh38Chr 14, 23425790: 23425790
52MYH7NM_000257.3(MYH7): c.2536G> C (p.Glu846Gln)SNVLikely pathogenic, Pathogenicrs730880748GRCh38Chr 14, 23424912: 23424912
53MYH7NM_000257.3(MYH7): c.2858A> T (p.Asp953Val)SNVPathogenicrs730880901GRCh38Chr 14, 23423971: 23423971
54MYH7NM_000257.3(MYH7): c.740T> G (p.Phe247Cys)SNVPathogenicrs730880922GRCh38Chr 14, 23431474: 23431474
55TNNI3NM_000363.4(TNNI3): c.407G> A (p.Arg136Gln)SNVLikely pathogenic, Pathogenicrs730881069GRCh37Chr 19, 55665540: 55665540
56TCAPNM_003673.3(TCAP): c.208C> T (p.Arg70Trp)SNVPathogenicrs775636212GRCh37Chr 17, 37822066: 37822066
57MYH7NM_000257.3(MYH7): c.1478T> A (p.Met493Lys)SNVLikely pathogenicrs786205905GRCh37Chr 14, 23897809: 23897809
58TTNNM_001256850.1(TTN): c.50509+5G> CSNVPathogenicrs754717390GRCh37Chr 2, 179466380: 179466380
59MYBPC3NM_000256.3(MYBPC3): c.2065C> T (p.Gln689Ter)SNVLikely pathogenic, Pathogenicrs863224483GRCh38Chr 11, 47339653: 47339653
60MYH7NM_000257.3(MYH7): c.4992C> A (p.Asn1664Lys)SNVLikely pathogenicrs763538103GRCh37Chr 14, 23885003: 23885003
61MYH7NM_000257.3(MYH7): c.2655T> A (p.Asn885Lys)SNVLikely pathogenicrs863225095GRCh37Chr 14, 23894002: 23894002
62MYH7NM_000257.3(MYH7): c.3645G> C (p.Gln1215His)SNVLikely pathogenicrs863225096GRCh37Chr 14, 23889135: 23889135
63MYH7NM_000257.3(MYH7): c.2201A> C (p.Gln734Pro)SNVLikely pathogenicrs863225097GRCh37Chr 14, 23894989: 23894989
64MYH7NM_000257.3(MYH7): c.3358G> A (p.Glu1120Lys)SNVLikely pathogenicrs863225098GRCh37Chr 14, 23889422: 23889422
65MYH7NM_000257.3(MYH7): c.2542_2544delGAG (p.Glu848del)deletionLikely pathogenicrs863225099GRCh38Chr 14, 23424904: 23424906
66MYH7NM_000257.3(MYH7): c.2893G> A (p.Glu965Lys)SNVLikely pathogenicrs863225100GRCh37Chr 14, 23893145: 23893145
67MYH7NM_000257.3(MYH7): c.5422G> A (p.Gly1808Ser)SNVLikely pathogenicrs369940645GRCh37Chr 14, 23884341: 23884341
68MYH7NM_000257.3(MYH7): c.4571A> G (p.His1524Arg)SNVLikely pathogenicrs767148171GRCh37Chr 14, 23886150: 23886150
69MYH7NM_000257.3(MYH7): c.2104A> G (p.Ile702Val)SNVLikely pathogenicrs863225101GRCh37Chr 14, 23895231: 23895231
70MYH7NM_000257.3(MYH7): c.1479G> C (p.Met493Ile)SNVLikely pathogenicrs730880876GRCh37Chr 14, 23897808: 23897808
71MYH7NM_000257.3(MYH7): c.755T> G (p.Phe252Cys)SNVLikely pathogenicrs727505202GRCh37Chr 14, 23900668: 23900668
72MYH7NM_000257.3(MYH7): c.2291T> A (p.Phe764Tyr)SNVLikely pathogenicrs863225102GRCh37Chr 14, 23894623: 23894623
73MYH7NM_000257.3(MYH7): c.2524A> G (p.Ser842Gly)SNVLikely pathogenicrs863225103GRCh37Chr 14, 23894133: 23894133
74MYBPC3NM_000256.3(MYBPC3): c.1302C> A (p.Tyr434Ter)SNVPathogenicrs190228518GRCh38Chr 11, 47343070: 47343070
75MYH6NM_002471.3(MYH6): c.3192dupC (p.Gln1065Profs)duplicationPathogenicrs863225269GRCh37Chr 14, 23862180: 23862180
76MYBPC3NM_000256.3(MYBPC3): c.1359delT (p.Val454Cysfs)deletionPathogenicrs863225271GRCh38Chr 11, 47342928: 47342928
77MYBPC3NM_000256.3(MYBPC3): c.3712_3713delCT (p.Leu1238Glyfs)deletionPathogenicrs863225272GRCh37Chr 11, 47353724: 47353725
78MYBPC3NM_000256.3(MYBPC3): c.1091-?_2308+?deldeletionPathogenicChr na, -1: -1
79MYBPC3NM_000256.3(MYBPC3): c.162delG (p.Lys54Asnfs)deletionPathogenicrs864622224GRCh37Chr 11, 47372920: 47372920
80PMPCANM_015160.2(PMPCA): c.1129G> A (p.Ala377Thr)SNVPathogenicrs753611141GRCh38Chr 9, 136418847: 136418847
81PMPCANM_015160.2(PMPCA): c.1066G> A (p.Gly356Ser)SNVPathogenicrs768643552GRCh37Chr 9, 139313082: 139313082
82MYBPC3NM_000256.3(MYBPC3): c.1236dupT (p.Glu413Terfs)duplicationPathogenicrs878853830GRCh37Chr 11, 47364687: 47364687
83MYBPC3NM_000256.3(MYBPC3): c.1633_1640delCTGGAGGT (p.Leu545Valfs)deletionPathogenicrs878853831GRCh37Chr 11, 47363692: 47363699
84MYBPC3NM_000256.3(MYBPC3): c.2234A> G (p.Asp745Gly)SNVPathogenicrs727503190GRCh37Chr 11, 47360145: 47360145
85MYBPC3NM_000256.3(MYBPC3): c.2618C> A (p.Pro873His)SNVPathogenicrs371401403GRCh37Chr 11, 47357547: 47357547
86CALR3NM_145046.4(CALR3): c.245A> G (p.Lys82Arg)SNVPathogenicrs142951029GRCh37Chr 19, 16601330: 16601330
87MYL3NM_000258.2(MYL3): c.170C> G (p.Ala57Gly)SNVPathogenicrs139794067GRCh37Chr 3, 46902303: 46902303
88TPM1NM_001018005.1(TPM1): c.644C> T (p.Ser215Leu)SNVLikely pathogenic, Pathogenicrs199476316GRCh37Chr 15, 63354418: 63354418
89TPM1NM_001018005.1(TPM1): c.842T> C (p.Met281Thr)SNVLikely pathogenic, Pathogenicrs199476321GRCh37Chr 15, 63356332: 63356332
90MYBPC3NM_000256.3(MYBPC3): c.2308G> A (p.Asp770Asn)SNVLikely pathogenic, Pathogenicrs36211723GRCh37Chr 11, 47360071: 47360071
91MYBPC3NM_000256.3(MYBPC3): c.2374T> C (p.Trp792Arg)SNVLikely pathogenic, Pathogenicrs187830361GRCh37Chr 11, 47359280: 47359280
92MYH7NM_000257.3(MYH7): c.5135G> A (p.Arg1712Gln)SNVLikely pathogenic, Pathogenicrs193922390GRCh37Chr 14, 23884860: 23884860
93MYBPC3NM_000256.3(MYBPC3): c.1235_1236delTT (p.Phe412Terfs)deletionPathogenicrs397515894GRCh37Chr 11, 47364687: 47364688
94MYBPC3NM_000256.3(MYBPC3): c.1468G> A (p.Gly490Arg)SNVPathogenicrs200625851GRCh37Chr 11, 47364285: 47364285
95MYBPC3NM_000256.3(MYBPC3): c.1504C> T (p.Arg502Trp)SNVPathogenicrs375882485GRCh37Chr 11, 47364249: 47364249
96MYBPC3NM_000256.3(MYBPC3): c.1505G> A (p.Arg502Gln)SNVLikely pathogenic, Pathogenicrs397515907GRCh37Chr 11, 47364248: 47364248
97MYBPC3NM_000256.3(MYBPC3): c.1624+4A> TSNVLikely pathogenic, Pathogenicrs397515916GRCh37Chr 11, 47364125: 47364125
98MYBPC3NM_000256.3(MYBPC3): c.1928-2A> GSNVPathogenicrs397515937GRCh37Chr 11, 47361343: 47361343
99MYBPC3NM_000256.3(MYBPC3): c.2096delC (p.Pro699Glnfs)deletionPathogenicrs397515947GRCh37Chr 11, 47360927: 47360927
100MYBPC3NM_000256.3(MYBPC3): c.2113dupA (p.Thr705Asnfs)duplicationPathogenicrs397515948GRCh37Chr 11, 47360910: 47360910
101MYBPC3NM_000256.3(MYBPC3): c.2308+1G> TSNVPathogenicrs112738974GRCh37Chr 11, 47360070: 47360070
102MYBPC3NM_000256.3(MYBPC3): c.2373dupG (p.Trp792Valfs)duplicationPathogenicrs397515963GRCh37Chr 11, 47359281: 47359281
103MYBPC3NM_000256.3(MYBPC3): c.2490dupT (p.His831Serfs)duplicationLikely pathogenic, Pathogenicrs397515966GRCh37Chr 11, 47359054: 47359054
104MYBPC3NM_000256.3(MYBPC3): c.2524dupT (p.Tyr842Leufs)duplicationPathogenicrs397515970GRCh37Chr 11, 47359020: 47359020
105MYBPC3NM_000256.3(MYBPC3): c.2670G> A (p.Trp890Ter)SNVLikely pathogenic, Pathogenicrs397515982GRCh37Chr 11, 47357495: 47357495
106MYBPC3NM_000256.3(MYBPC3): c.2864_2865delCT (p.Pro955Argfs)deletionLikely pathogenic, Pathogenicrs397515990GRCh37Chr 11, 47356633: 47356634
107MYBPC3NM_000256.3(MYBPC3): c.2905+1G> ASNVLikely pathogenic, Pathogenicrs397515991GRCh37Chr 11, 47356592: 47356592
108MYBPC3NM_000256.3(MYBPC3): c.2905C> T (p.Gln969Ter)SNVPathogenicrs397515992GRCh37Chr 11, 47356593: 47356593
109MYBPC3NM_000256.3(MYBPC3): c.3192dupC (p.Lys1065Glnfs)duplicationPathogenicrs397516007GRCh37Chr 11, 47354883: 47354883
110MYBPC3NM_000256.3(MYBPC3): c.3330+5G> CSNVLikely pathogenic, Pathogenicrs373746463GRCh37Chr 11, 47354740: 47354740
111MYBPC3NM_000256.3(MYBPC3): c.3624delC (p.Lys1209Serfs)deletionPathogenicrs397516030GRCh37Chr 11, 47354120: 47354120
112MYBPC3NM_000256.3(MYBPC3): c.3697C> T (p.Gln1233Ter)SNVLikely pathogenic, Pathogenicrs397516037GRCh37Chr 11, 47353740: 47353740
113MYBPC3NM_000256.3(MYBPC3): c.655G> C (p.Val219Leu)SNVLikely pathogenic, Pathogenicrs397516068GRCh37Chr 11, 47370092: 47370092
114MYBPC3NM_000256.3(MYBPC3): c.772+1G> ASNVLikely pathogenic, Pathogenicrs397516072GRCh37Chr 11, 47369974: 47369974
115MYBPC3NM_000256.3(MYBPC3): c.821+1G> ASNVLikely pathogenic, Pathogenicrs397516073GRCh37Chr 11, 47369407: 47369407
116MYBPC3NM_000256.3(MYBPC3): c.772G> A (p.Glu258Lys)SNVLikely pathogenic, Pathogenicrs397516074GRCh37Chr 11, 47369975: 47369975
117MYH7NM_000257.3(MYH7): c.1358G> A (p.Arg453His)SNVLikely pathogenic, Pathogenicrs397516101GRCh37Chr 14, 23898213: 23898213
118MYH7NM_000257.3(MYH7): c.1750G> A (p.Gly584Ser)SNVLikely pathogenic, Pathogenicrs121913626GRCh37Chr 14, 23896932: 23896932
119MYH7NM_000257.3(MYH7): c.1988G> A (p.Arg663His)SNVLikely pathogenic, Pathogenicrs371898076GRCh37Chr 14, 23896042: 23896042
120MYH7NM_000257.3(MYH7): c.2093T> C (p.Val698Ala)SNVPathogenicrs397516130GRCh37Chr 14, 23895242: 23895242
121MYH7NM_000257.3(MYH7): c.2167C> G (p.Arg723Gly)SNVLikely pathogenic, Pathogenicrs121913630GRCh37Chr 14, 23895023: 23895023
122MYH7NM_000257.3(MYH7): c.2389G> A (p.Ala797Thr)SNVLikely pathogenic, Pathogenicrs3218716GRCh37Chr 14, 23894525: 23894525
123MYH7NM_000257.3(MYH7): c.2513C> T (p.Pro838Leu)SNVPathogenicrs397516153GRCh37Chr 14, 23894144: 23894144
124MYH7NM_000257.3(MYH7): c.4135G> A (p.Ala1379Thr)SNVLikely pathogenic, Pathogenicrs397516202GRCh37Chr 14, 23887453: 23887453
125MYH7NM_000257.3(MYH7): c.428G> A (p.Arg143Gln)SNVLikely pathogenic, Pathogenicrs397516209GRCh37Chr 14, 23901922: 23901922
126MYH7NM_000257.3(MYH7): c.438G> T (p.Lys146Asn)SNVLikely pathogenic, Pathogenicrs397516212GRCh37Chr 14, 23901912: 23901912
127MYH7NM_000257.3(MYH7): c.715G> A (p.Asp239Asn)SNVLikely pathogenic, Pathogenicrs397516264GRCh37Chr 14, 23900811: 23900811
128MYH7NM_000257.3(MYH7): c.788T> C (p.Ile263Thr)SNVLikely pathogenic, Pathogenicrs397516269GRCh37Chr 14, 23900635: 23900635
129TNNI3NM_000363.4(TNNI3): c.434G> A (p.Arg145Gln)SNVLikely pathogenic, Pathogenicrs397516349GRCh37Chr 19, 55665513: 55665513
130TNNI3NM_000363.4(TNNI3): c.485G> A (p.Arg162Gln)SNVLikely pathogenic, Pathogenicrs397516354GRCh37Chr 19, 55665462: 55665462
131TNNI3NM_000363.4(TNNI3): c.557G> A (p.Arg186Gln)SNVPathogenicrs397516357GRCh37Chr 19, 55663278: 55663278
132TNNT2NM_000364.3(TNNT2): c.877C> T (p.Arg293Cys)SNVLikely pathogenic, Pathogenicrs367785431GRCh37Chr 1, 201328349: 201328349
133MYBPC3NM_000256.3(MYBPC3): c.1624G> C (p.Glu542Gln)SNVLikely pathogenic, Pathogenicrs121909374GRCh37Chr 11, 47364129: 47364129
134MYBPC3NM_000256.3(MYBPC3): c.3330+2T> GSNVLikely pathogenic, Pathogenicrs387906397GRCh37Chr 11, 47354743: 47354743

Expression for genes affiliated with Cardiomyopathy, Familial Hypertrophic

About this section
Search GEO for disease gene expression data for Cardiomyopathy, Familial Hypertrophic.

Pathways for genes affiliated with Cardiomyopathy, Familial Hypertrophic

About this section

Pathways related to Cardiomyopathy, Familial Hypertrophic according to KEGG:

34
id Name KEGG Source Accession
1Hypertrophic cardiomyopathy (HCM)hsa05410

Pathways related to Cardiomyopathy, Familial Hypertrophic according to GeneCards Suite gene sharing:

(show all 15)
idSuper pathwaysScoreTop Affiliating Genes
110.3MYH7, MYL2
210.3MYH6, MYH7, PRKAG2
310.2MYL3, TNNI3, TNNT2
410.2MYH6, MYH7, MYL2, MYL3
5
Show member pathways
10.2MYH6, MYH7, MYL2, MYL3
610.2ACTN2, MYH6, MYH7, MYL2
710.1ACTC1, TNNI3, TNNT2, TPM1
8
Show member pathways
10.1ACTN2, MYH6, MYH7, MYL2, MYL3
910.1ACTC1, MYH6, MYL2, TNNI3, TNNT2
10
Show member pathways
10.0ACTN2, MYH6, MYH7, MYL2, MYL3, MYLK2
11
Show member pathways
9.9ACTC1, ACTN2, MYH6, MYH7, MYL2, MYL3
129.9ACTC1, MYH6, MYH7, MYL2, MYL3, TNNI3
13
Show member pathways
9.8ACTC1, MYH6, MYH7, MYL2, MYL3, MYLK2
14
Show member pathways
9.6ACTN2, CAV3, MYBPC3, MYH6, MYL2, MYL3
159.6ACTC1, ACTN2, MYBPC3, MYH6, MYL2, MYL3

GO Terms for genes affiliated with Cardiomyopathy, Familial Hypertrophic

About this section

Cellular components related to Cardiomyopathy, Familial Hypertrophic according to GeneCards Suite gene sharing:

(show all 11)
idNameGO IDScoreTop Affiliating Genes
1A bandGO:003167211.0MYBPC3, MYL2, MYL3
2myosin filamentGO:003298210.9MYH6, MYH7
3troponin complexGO:000586110.9TNNI3, TNNT2
4muscle myosin complexGO:000585910.8MYH6, MYH7, MYL3, TTN
5stress fiberGO:000172510.8MYH6, MYH7, TPM1
6myosin complexGO:001645910.8MYH6, MYH7, MYL2, MYL3
7I bandGO:003167410.8ACTC1, MYL3, TCAP, TTN
8myofibrilGO:003001610.6MYH6, MYH7, MYL2, TNNI3, TNNT2, TPM1
9sarcomereGO:003001710.1ACTC1, ACTN2, MYBPC3, MYH6, MYH7, MYL2
10cytosolGO:000582910.0ACTC1, ACTN2, CAV3, JPH2, MYBPC3, MYH6
11Z discGO:00300189.7ACTN2, CAV3, CSRP3, JPH2, MYH6, MYH7

Biological processes related to Cardiomyopathy, Familial Hypertrophic according to GeneCards Suite gene sharing:

(show all 30)
idNameGO IDScoreTop Affiliating Genes
1actin filament-based movementGO:003004811.0ACTC1, MYH6
2cardiac muscle cell developmentGO:005501311.0ACTN2, CAV3
3negative regulation of ATPase activityGO:003278010.9TNNI3, TNNT2
4adult heart developmentGO:000751210.9MYH6, MYH7, TCAP
5cardiac muscle hypertrophy in response to stressGO:001489810.9MYH6, MYH7, TCAP
6negative regulation of potassium ion transmembrane transporter activityGO:190101710.9ACTN2, CAV3
7negative regulation of protein localization to cell surfaceGO:200000910.9ACTN2, CAV3
8cardiac muscle fiber developmentGO:004873910.9MYH6, TCAP, TTN
9regulation of muscle filament slidingGO:003297110.9MYBPC3, MYLK2
10heart contractionGO:006004710.9ACTC1, MYL2, TNNI3
11cardiac muscle hypertrophyGO:000330010.9CSRP3, TCAP, TTN
12regulation of heart rateGO:000202710.9CAV3, MYH6, MYH7
13cardiac muscle tissue morphogenesisGO:005500810.8ACTC1, MYLK2, TCAP, TTN
14sarcomerogenesisGO:004876910.8TCAP, TTN
15detection of muscle stretchGO:003599510.8CAV3, CSRP3, TCAP, TTN
16regulation of striated muscle contractionGO:000694210.8MYBPC3, MYL2, MYL3
17regulation of muscle contractionGO:000693710.8TNNI3, TNNT2, TPM1
18skeletal muscle myosin thick filament assemblyGO:003024110.8TCAP, TTN
19positive regulation of ATPase activityGO:003278110.7MYBPC3, MYL3, TNNT2, TPM1
20regulation of heart contractionGO:000801610.7CAV3, MYH6, TNNT2, TPM1
21skeletal muscle contractionGO:000300910.7MYH7, TCAP, TNNI3
22cardiac myofibril assemblyGO:005500310.7ACTC1, CSRP3, MYL2, TCAP, TTN
23skeletal muscle thin filament assemblyGO:003024010.7ACTC1, TCAP, TTN
24regulation of the force of heart contractionGO:000202610.6CSRP3, MYH6, MYH7, MYL2, MYL3
25sarcomere organizationGO:004521410.6ACTN2, MYH6, TCAP, TPM1, TTN
26muscle contractionGO:000693610.5ACTN2, CAV3, MYH6, MYH7, TNNT2, TPM1
27striated muscle contractionGO:000694110.5MYH6, MYH7, MYLK2, TNNI3, TTN
28muscle filament slidingGO:003004910.1ACTC1, ACTN2, MYBPC3, MYH6, MYH7, MYL2
29cardiac muscle contractionGO:006004810.1ACTC1, CSRP3, MYBPC3, MYH6, MYH7, MYL2
30ventricular cardiac muscle tissue morphogenesisGO:00550109.9MYBPC3, MYH6, MYH7, MYL2, MYL3, TNNI3

Molecular functions related to Cardiomyopathy, Familial Hypertrophic according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1actin-dependent ATPase activityGO:003089811.0MYH6, MYH7
2actinin bindingGO:004280510.9CSRP3, TTN
3FATZ bindingGO:005137310.9ACTN2, TCAP
4microfilament motor activityGO:000014610.9MYH6, MYH7
5myosin bindingGO:001702210.8ACTC1, MYBPC3
6myosin heavy chain bindingGO:003203610.8MYBPC3, MYL2
7calmodulin bindingGO:000551610.8MYH6, MYH7, MYLK2, TTN
8ion channel bindingGO:004432510.8ACTN2, CAV3, TCAP
9actin bindingGO:000377910.6MYBPC3, MYH6, MYH7, MYOZ2, TNNI3, TNNT2
10telethonin bindingGO:003143310.6CSRP3, MYOZ2, TTN
11titin bindingGO:003143210.3ACTN2, MYBPC3, TCAP
12troponin C bindingGO:003017210.3TNNI3, TNNT2
13titin Z domain bindingGO:007008010.3ACTN2, TCAP
14structural constituent of muscleGO:000830710.2ACTN2, CSRP3, MYBPC3, MYL2, MYL3, TCAP

Sources for Cardiomyopathy, Familial Hypertrophic

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet